Stock Scorecard



Stock Summary for Lipella Pharmaceuticals Inc (LIPO) - $0.90 as of 6/28/2025 4:11:48 AM EST

Total Score

12 out of 30

Safety Score

13 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for LIPO

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for LIPO

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for LIPO

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for LIPO

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for LIPO (13 out of 100)

Stock Price Rating (Max of 10) 1
Historical Stock Price Rating (Max of 10) 1
Stock Price Trend (Max of 10) 0
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 8
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 1
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for LIPO

Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting 6/25/2025 7:15:00 PM
Crude Oil Falls 1%; US Services PMI Declines In June - Compass Pathways ( NASDAQ:CMPS ) , Cidara Therapeutics ( NASDAQ:CDTX ) 6/23/2025 4:33:00 PM
Dow Jumps Over 200 Points; FactSet Research Shares Gain After Q3 Results - Compass Pathways ( NASDAQ:CMPS ) , Cidara Therapeutics ( NASDAQ:CDTX ) 6/23/2025 2:51:00 PM
Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market - Lipella Pharmaceuticals ( NASDAQ:LIPO ) 6/20/2025 7:19:00 PM
Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market 6/20/2025 7:19:00 PM
Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology - Lipella Pharmaceuticals ( NASDAQ:LIPO ) 6/17/2025 12:30:00 PM
Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development - Lipella Pharmaceuticals ( NASDAQ:LIPO ) 6/4/2025 12:30:00 PM
Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025 4/22/2025 9:30:00 AM
Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus 4/8/2025 9:00:00 AM
Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast 3/31/2025 3:00:00 PM

Financial Details for LIPO

Company Overview

Ticker LIPO
Company Name Lipella Pharmaceuticals Inc
Country USA
Description N/A
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 3/31/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 0.90
Price 4 Years Ago 0.00
Last Day Price Updated 6/28/2025 4:11:48 AM EST
Last Day Volume 19,002
Average Daily Volume 63,000
52-Week High 7.75
52-Week Low 0.62
Last Price to 52 Week Low 45.16%

Valuation Measures

Trailing PE N/A
Industry PE 22.52
Sector PE 40.73
5-Year Average PE -2.14
Free Cash Flow Ratio 0.00
Industry Free Cash Flow Ratio 17.94
Sector Free Cash Flow Ratio 32.54
Current Ratio Most Recent Quarter 6.21
Total Cash Per Share 945.74
Book Value Per Share Most Recent Quarter 1.60
Price to Book Ratio 0.99
Industry Price to Book Ratio 35.01
Sector Price to Book Ratio 30.79
Price to Sales Ratio Twelve Trailing Months 7.73
Industry Price to Sales Ratio Twelve Trailing Months 123.25
Sector Price to Sales Ratio Twelve Trailing Months 35.57
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics

Total Shares Outstanding 4,467,400
Market Capitalization 4,020,660
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -8.60%
Reported EPS 12 Trailing Months -4.12
Reported EPS Past Year -0.64
Reported EPS Prior Year -3.60
Net Income Twelve Trailing Months -1,310,347,455
Net Income Past Year -5,016,264
Net Income Prior Year -4,618,965
Quarterly Revenue Growth YOY -11.30%
5-Year Revenue Growth -5.04%
Operating Margin Twelve Trailing Months -1,026.00%

Balance Sheet

Total Cash Most Recent Quarter 4,225,012,000
Total Cash Past Year 2,184,863
Total Cash Prior Year 3,293,738
Net Cash Position Most Recent Quarter 4,225,012,000
Net Cash Position Past Year 2,159,863
Long Term Debt Past Year 25,000
Long Term Debt Prior Year 25,000
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 0.99
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 1,919,453
Total Stockholder Equity Prior Year 3,144,448
Total Stockholder Equity Most Recent Quarter 4,079,204,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -1,428,688,308
Free Cash Flow Per Share Twelve Trailing Months -319.80
Free Cash Flow Past Year -3,950,747
Free Cash Flow Prior Year -3,164,606

Options

Put/Call Ratio 0.00
Has Options False
Liquidity Rating None

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.44
MACD Signal -0.21
20-Day Bollinger Lower Band 1.37
20-Day Bollinger Middle Band 2.52
20-Day Bollinger Upper Band 3.67
Beta 0.46
RSI 26.32
50-Day SMA 0.00
150-Day SMA 0.00
200-Day SMA 0.00

System

Modified 6/28/2025 4:12:35 AM EST